Monoclonal Antibody Treatment Authorized for Immunocompromised Persons

December 9, 2021

Last night, the FDA authorized a COVID-19 monoclonal antibody treatment by AstraZeneca for immunocompromised individuals, who did not produce sufficient antibodies following vaccination. This includes patients taking immunosuppressants. Evusheld was specifically developed to metabolize over a matter of months – perhaps up to six – meaning it offers longer-lasting protection against COVID-19.

Evusheld differs from other monoclonal antibody treatments, such as Eli Lilly’s or Merck’s, in that it is administered as a long-acting prophylactic (disease preventative) as opposed to being a treatment for those already infected by Covid or short-term protective treatment. Evusheld is not authorized for those already infected with COVID-19, nor those who have been exposed to someone with COVID-19.

In its clinical trial, AstraZeneca’s Evusheld reduced the risk of symptomatic infection by 83%; these results included both immunocompromised and immunocompetent participants. The treatment includes two separate intramuscular injections given back-to-back, each with one monoclonal antibody. “Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. Tixagevimab and cilgavimab are long-acting monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells. Tixagevimab and cilgavimab bind to different, non-overlapping sites on the spike protein of the virus.”

Evusheld will be available for certain adults as well as pediatric patients 12+ years of age.





Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.